Articles related to Radiation Oncology

Daraxonrasib, an oral RAS(ON) inhibitor, doubled overall survival and progression-free survival versus chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma across RAS-mutated and wild-type disease in a phase 3 trial.

A phase 3 randomized trial of 449 children with intracranial ependymoma found no significant event-free or overall survival benefit from adding maintenance chemotherapy after radiation, while molecular markers — particularly 1q gain and 6q loss — identified a high-risk posterior fossa subgroup with substantially worse outcomes.

A gynecologic oncologist reviews the current role of immune checkpoint inhibition across locally advanced and recurrent cervical cancer settings, including KEYNOTE-A18 survival data, key regulatory distinctions, and unanswered sequencing questions.

A community oncologist previewed four ASCO 2026 late-breaking abstracts spanning pancreatic, prostate, lung, and sarcoma, flagging molecular testing infrastructure and toxicity coordination as key implementation questions ahead of the data readout.

Opioid prescribing for cancer patients reporting no pain declined substantially across a single Connecticut health system from 2016 to 2020, while prescribing for patients reporting pain remained stable.

Adding niraparib to abiraterone prolonged radiographic progression-free survival in BRCA-mutant metastatic hormone-sensitive prostate cancer, with overall survival data still maturing.